[go: up one dir, main page]

SI3668513T1 - Aktivatorji piruvat kinaze za uporabo pri zdravljenju krvnih obolenj - Google Patents

Aktivatorji piruvat kinaze za uporabo pri zdravljenju krvnih obolenj

Info

Publication number
SI3668513T1
SI3668513T1 SI201830558T SI201830558T SI3668513T1 SI 3668513 T1 SI3668513 T1 SI 3668513T1 SI 201830558 T SI201830558 T SI 201830558T SI 201830558 T SI201830558 T SI 201830558T SI 3668513 T1 SI3668513 T1 SI 3668513T1
Authority
SI
Slovenia
Prior art keywords
pyruvate kinase
blood disorders
treating blood
kinase activators
activators
Prior art date
Application number
SI201830558T
Other languages
English (en)
Inventor
Giovanni Cianchetta
Tao Liu
Anil Kumar Padyana
Zhihua Sui
Zhenwei Cai
Dawei Cui
Jingjing Ji
Original Assignee
Agios Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.
Publication of SI3668513T1 publication Critical patent/SI3668513T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201830558T 2017-08-15 2018-08-15 Aktivatorji piruvat kinaze za uporabo pri zdravljenju krvnih obolenj SI3668513T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017097496 2017-08-15
US201862673526P 2018-05-18 2018-05-18
US201862673533P 2018-05-18 2018-05-18
PCT/US2018/000128 WO2019035864A1 (en) 2017-08-15 2018-08-15 PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS
EP18779068.8A EP3668513B1 (en) 2017-08-15 2018-08-15 Pyruvate kinase activators for use in treating blood disorders

Publications (1)

Publication Number Publication Date
SI3668513T1 true SI3668513T1 (sl) 2022-04-29

Family

ID=63524352

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201830914T SI3668512T1 (sl) 2017-08-15 2018-08-15 Modulatorji piruvat kinaze in njihova uporaba
SI201830558T SI3668513T1 (sl) 2017-08-15 2018-08-15 Aktivatorji piruvat kinaze za uporabo pri zdravljenju krvnih obolenj

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201830914T SI3668512T1 (sl) 2017-08-15 2018-08-15 Modulatorji piruvat kinaze in njihova uporaba

Country Status (34)

Country Link
US (8) US11464775B2 (sl)
EP (4) EP4026838A1 (sl)
JP (5) JP7301040B2 (sl)
KR (3) KR102717594B1 (sl)
CN (3) CN111032046B (sl)
AU (4) AU2018316588B2 (sl)
BR (2) BR112020003262A2 (sl)
CA (2) CA3071993A1 (sl)
CL (1) CL2020000375A1 (sl)
CO (2) CO2020002959A2 (sl)
CR (1) CR20200123A (sl)
CY (1) CY1124953T1 (sl)
DK (2) DK3668512T3 (sl)
EC (1) ECSP20018487A (sl)
ES (3) ES2905100T3 (sl)
FI (1) FI3668512T3 (sl)
HR (2) HRP20230452T1 (sl)
HU (2) HUE057178T2 (sl)
IL (3) IL272599B (sl)
LT (2) LT3668513T (sl)
MD (1) MD3668513T2 (sl)
MX (2) MX2020001832A (sl)
MY (1) MY204421A (sl)
PE (1) PE20200724A1 (sl)
PH (1) PH12020500343B1 (sl)
PL (2) PL3668513T3 (sl)
PT (2) PT3668513T (sl)
RS (2) RS62871B1 (sl)
SG (2) SG11202001353PA (sl)
SI (2) SI3668512T1 (sl)
SM (2) SMT202200023T1 (sl)
TW (3) TWI796353B (sl)
UA (1) UA126292C2 (sl)
WO (3) WO2019035863A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3448859T3 (da) 2017-03-20 2019-09-23 Forma Therapeutics Inc Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
US12233063B2 (en) 2017-10-20 2025-02-25 The Regents Of The University Of Michigan Compositions and methods for treating eye disorders
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
JP7450610B2 (ja) 2018-09-19 2024-03-15 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー ピルビン酸キナーゼｒの活性化
CN113646050A (zh) * 2019-02-13 2021-11-12 安吉奥斯医药品有限公司 噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途
WO2020262419A1 (ja) * 2019-06-26 2020-12-30 日産化学株式会社 電荷輸送性ワニス
MX2022003254A (es) 2019-09-19 2022-04-18 Forma Therapeutics Inc Composiciones activadoras de piruvato cinasa r (pkr).
JP2023535027A (ja) * 2020-07-21 2023-08-15 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ピルビン酸キナーゼを活性化するための組成物及び方法
CN112490502B (zh) * 2020-12-04 2022-01-21 广州天赐高新材料股份有限公司 一种电解液及锂二次电池
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
EP4408845A1 (en) * 2021-09-30 2024-08-07 Sitryx Therapeutics Limited Novel compounds
EP4433057A1 (en) * 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) * 2023-03-09 2023-05-26 上海市第十人民医院 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
TW202509043A (zh) 2023-05-15 2025-03-01 美商阿吉歐斯製藥公司 ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式
WO2025010390A1 (en) * 2023-07-05 2025-01-09 Agios Pharmaceuticals, Inc. Synthesis of pyruvate kinase activators
WO2025207563A1 (en) 2024-03-27 2025-10-02 Agios Pharmaceuticals, Inc. Use of a pk activator in the treatment of sickle cell disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405635A (en) 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en) 1987-08-17 1989-11-28 American Cyanamid Company Benzenesulfonyl carboxamide compounds useful as herbicidal agents
AU6388900A (en) 1999-07-30 2001-02-19 Abbott Gmbh & Co. Kg 2-pyrazolin-5-ones
DE60009319T2 (de) 1999-09-04 2005-03-31 Astrazeneca Ab Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität
EP1972629A1 (en) * 2007-03-23 2008-09-24 Mutabilis SA New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) * 2008-07-15 2010-08-27 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2011529066A (ja) * 2008-07-23 2011-12-01 バーテックス ファーマシューティカルズ インコーポレイテッド 三環式ピラゾロピリジンキナーゼ阻害剤
US8420649B2 (en) * 2008-08-29 2013-04-16 Amgen Inc. Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
CA3041868C (en) 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
EP2417123A2 (en) * 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
CA2944788C (en) 2009-06-29 2023-08-22 Agios Pharmaceuticals, Inc. Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same
US20130109672A1 (en) 2010-04-29 2013-05-02 The United States Of America,As Represented By The Secretary, Department Of Health And Human Service Activators of human pyruvate kinase
JP5886310B2 (ja) 2010-12-06 2016-03-16 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｌｐ−ＰＬＡ２により媒介される疾患または状態の処置における使用のためのピリミジノン化合物
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
US9388164B2 (en) 2011-05-03 2016-07-12 Agios Pharmaceuticals, Inc Methods of using pyruvate kinase activators
ES2668213T3 (es) 2011-05-03 2018-05-17 Agios Pharmaceuticals, Inc. Uso de activadores de piruvato quinasa para aumentar la vida útil de los glóbulos rojos de la sangre y tratar la anemia
KR101873543B1 (ko) * 2011-05-03 2018-07-02 아지오스 파마슈티컬스 아이엔씨. 치료에 사용하기 위한 피루베이트 키나아제 활성제
CA2834692A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
AU2012284088B2 (en) * 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013056153A1 (en) * 2011-10-13 2013-04-18 Kung Charles Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
US9458132B2 (en) * 2012-11-08 2016-10-04 Agios Pharmaceuticals, Inc Therapeutic compounds and compositions and their use as PKM2 modulators
CA2899352A1 (en) * 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
JP6545148B2 (ja) 2013-03-13 2019-07-17 フラットリー ディスカバリー ラブ，エルエルシー ピリダジノン化合物及び嚢胞性線維症の治療のための方法
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
PT3661925T (pt) 2017-07-07 2022-01-31 Inflazome Ltd Novos compostos de sulfonamida-carboxamida
JP2020531453A (ja) 2017-08-15 2020-11-05 インフレイゾーム リミテッド Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア
TWI796353B (zh) 2017-08-15 2023-03-21 美商阿吉歐斯製藥公司 丙酮酸激酶調節劑及其用途
AR112475A1 (es) 2017-08-15 2019-10-30 Agios Pharmaceuticals Inc Moduladores de piruvato quinasas y uso de los mismos
SG10202106345VA (en) 2017-08-15 2021-07-29 Abbvie Inc Macrocyclic mcl-1 inhibitors and methods of use
CN113646050A (zh) * 2019-02-13 2021-11-12 安吉奥斯医药品有限公司 噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途

Also Published As

Publication number Publication date
EP3668881A1 (en) 2020-06-24
WO2019035865A1 (en) 2019-02-21
CN111032046B (zh) 2023-09-26
EP3668881B1 (en) 2023-10-04
JP7301040B2 (ja) 2023-06-30
IL272599A (en) 2020-03-31
RS64221B1 (sr) 2023-06-30
PL3668513T3 (pl) 2022-03-21
IL292530B2 (en) 2023-06-01
AU2024205818A1 (en) 2024-09-05
US12133853B2 (en) 2024-11-05
RU2020110573A (ru) 2021-09-16
WO2019035865A8 (en) 2019-03-28
EP3668512A1 (en) 2020-06-24
US20210130371A1 (en) 2021-05-06
CN111032046A (zh) 2020-04-17
CA3072455A1 (en) 2019-02-21
AU2018316588B2 (en) 2023-02-02
UA126292C2 (uk) 2022-09-14
ECSP20018487A (es) 2020-05-29
CN111032045A (zh) 2020-04-17
US20210077490A1 (en) 2021-03-18
PH12020500343B1 (en) 2024-02-21
JP7530453B2 (ja) 2024-08-07
KR102764124B1 (ko) 2025-02-05
WO2019035864A1 (en) 2019-02-21
AU2018316588A1 (en) 2020-02-20
CL2020000375A1 (es) 2020-12-11
FI3668512T3 (fi) 2023-05-12
WO2019035863A8 (en) 2019-03-28
SMT202300146T1 (it) 2023-07-20
RS62871B1 (sr) 2022-02-28
TWI796353B (zh) 2023-03-21
TW202323258A (zh) 2023-06-16
US11957680B2 (en) 2024-04-16
IL272597B (en) 2022-06-01
KR102717594B1 (ko) 2024-10-14
MD3668513T2 (ro) 2022-04-30
KR20200054200A (ko) 2020-05-19
DK3668512T3 (da) 2023-05-22
CN111032045B (zh) 2023-08-15
AU2018316587B2 (en) 2023-05-11
HUE057178T2 (hu) 2022-04-28
CN117186119A (zh) 2023-12-08
CO2020002959A2 (es) 2020-04-13
CA3071993A1 (en) 2019-02-21
MY204421A (en) 2024-08-28
JP2020531443A (ja) 2020-11-05
US20230226055A1 (en) 2023-07-20
US20200207785A1 (en) 2020-07-02
PL3668512T3 (pl) 2023-06-19
US11364240B2 (en) 2022-06-21
WO2019035864A8 (en) 2019-03-28
KR102642408B1 (ko) 2024-02-28
US20200206225A1 (en) 2020-07-02
SG11202001353PA (en) 2020-03-30
PT3668512T (pt) 2023-05-22
KR20200054199A (ko) 2020-05-19
HUE061910T2 (hu) 2023-08-28
LT3668512T (lt) 2023-06-12
US20220233541A1 (en) 2022-07-28
AU2023202772A1 (en) 2023-05-18
US11872225B2 (en) 2024-01-16
TW201919631A (zh) 2019-06-01
JP2020531432A (ja) 2020-11-05
JP7275107B2 (ja) 2023-05-17
SMT202200023T1 (it) 2022-03-21
HRP20230452T1 (hr) 2023-07-21
LT3668513T (lt) 2022-03-25
CY1124953T1 (el) 2023-01-05
DK3668513T3 (da) 2022-01-10
PT3668513T (pt) 2022-01-21
TWI823580B (zh) 2023-11-21
ES2966825T3 (es) 2024-04-24
AU2023202772B2 (en) 2024-05-16
IL272597A (en) 2020-03-31
JP2023027276A (ja) 2023-03-01
ES2944545T3 (es) 2023-06-22
CO2020002961A2 (es) 2020-04-13
MX2020001832A (es) 2020-07-22
US11590132B2 (en) 2023-02-28
SI3668512T1 (sl) 2023-06-30
US11464775B2 (en) 2022-10-11
AU2018316587A1 (en) 2020-02-20
ES2905100T3 (es) 2022-04-07
EP3668512B1 (en) 2023-02-15
BR112020003254A2 (pt) 2020-10-27
US11040036B2 (en) 2021-06-22
IL272599B (en) 2022-08-01
CR20200123A (es) 2020-06-29
MX2020001833A (es) 2020-07-22
TWI790271B (zh) 2023-01-21
HRP20220039T1 (hr) 2022-04-15
PH12020500343A1 (en) 2021-02-08
EP3668513B1 (en) 2021-11-10
PE20200724A1 (es) 2020-07-21
RU2020110573A3 (sl) 2021-12-24
TW201920203A (zh) 2019-06-01
IL292530A (en) 2022-06-01
US20220395503A1 (en) 2022-12-15
JP2024147805A (ja) 2024-10-16
BR112020003262A2 (pt) 2020-09-01
KR20230127364A (ko) 2023-08-31
EP3668513A1 (en) 2020-06-24
US20250144093A1 (en) 2025-05-08
JP2023052478A (ja) 2023-04-11
EP4026838A1 (en) 2022-07-13
WO2019035863A1 (en) 2019-02-21
SG11202001262QA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
IL292530B2 (en) Pyruvate kinase activators for use in the treatment of blood disorders
IL288231A (en) An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
HRP20210518T1 (hr) Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
IL256166B (en) Compounds for use in the treatment of neuromuscular disorders
PT3882250T (pt) Tetrahidropiranil amino-pirrolopirimidinona e métodos de utilização da mesma
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
ZA201902320B (en) 17alpha,21-diesters of cortexolone for use in the treatment of tumors
IL271020A (en) Tinostemustine for the treatment of sarcoma
HUE039750T2 (hu) Hidroxi-buspiron mozgászavarok kezelésére
GB201702160D0 (en) Inhibitors for use in therapy
ZA201802399B (en) Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
IL253933A0 (en) History of pyrimidine use in the treatment of cancer
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
GB201615844D0 (en) Agents for use in therapy
HK40030323A (en) Pyruvate kinase activators for use in treating blood disorders